TICKERNERD
Menu
TEMTEMHealthcare · Health Information Services

TEM Stock Forecast: Tempus AI, Inc. Price Predictions for 2026-2027

Last close, 21 Aug 2026
$73
+9.06% on the day

The 16 Wall Street analysts covering Tempus AI, Inc. hold a median 12-month price target of $59 — -18.8% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 25 of 100 as at 21 Aug 2026 — in the lower half.

Market cap
$13.1B
Ticker Nerd rank
25 / 100
Median analyst target
$59
Analysts covering
16
Total return, dividends reinvested
1W
+39.5%
1M
+48.4%
YTD
+23.1%
1Y
−5.2%
From 52W high
−29.6%
From 52W low
+74.9%
$42
$103
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

TEM stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Tempus AI, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Aug 2026
25 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
80
Quality
55
Value
47
Growth
46
Momentum
39
Accruals
23
Volatility
17
Issuance
16
Size
13

Revisions (80): Analysts have, on balance, been raising their forecasts.

Issuance (16): The company has been issuing shares or taking on financing, diluting existing holders.

Size (13): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

TEM stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on TEM, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$40$60$80$100Oct 25Jan 26Apr 26Jul 26TEMHigh $100Median $59Low $35

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says16 analysts
8 Buy7 Hold1 Sell
Low $35Median $59High $100

The green dot is the last close — the median target sits −18.8% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 2 moved their price target up and 4 moved it down.

DateFirmActionRatingTarget
20 Aug 2026BTIGMaintainsBuy$70 → $80
4 Aug 2026Piper SandlerMaintainsNeutral$58 → $56
4 Aug 2026Piper SandlerMaintainsNeutral—
3 Aug 2026BTIGMaintainsBuy$80 → $70
3 Aug 2026BTIGMaintainsBuy—
3 Aug 2026HC Wainwright & Co.MaintainsBuy—
3 Aug 2026HC Wainwright & Co.MaintainsBuy$64 → $56
3 Aug 2026StifelMaintainsHold$60 → $50
3 Aug 2026StifelMaintainsHold—
31 July 2026NeedhamReiteratesBuy$75
31 July 2026NeedhamReiteratesBuy—
20 July 2026NeedhamReiteratesBuy$75
20 July 2026NeedhamReiteratesBuy—
16 July 2026GuggenheimMaintainsBuy$60 → $65
16 July 2026GuggenheimMaintainsBuy—
1 July 2026Freedom Capital MarketsInitiatesHold$59
1 July 2026Freedom Capital MarketsInitiatesHold—
1 June 2026BTIGReiteratesBuy—
1 June 2026NeedhamReiteratesBuy—
11 May 2026HC Wainwright & Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. TEM appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

TEM analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
9
Analysts cutting
1
Fundamentals

Tempus AI, Inc. (TEM) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
39.3×

Cheaper than 20% of US stocks

Price / sales
9.2×

Cheaper than 17% of US stocks

Price / book
29.4×

Cheaper than 4% of US stocks

EV / EBITDA
−71.1×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
21.6%

Higher than 71% of US stocks

Earnings growth (YoY)
21.6%

Higher than 60% of US stocks

Gross margin
64.4%

Higher than 78% of US stocks

Operating margin
−20.1%

Higher than 21% of US stocks

Net margin
−17.8%

Higher than 16% of US stocks

Returns & dividend
Return on equity
−67.4%

Higher than 17% of US stocks

Return on assets
−8.5%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

TEM vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelHealth Information Services
CompanyMarket capTKN rank
TEMTempus AI, Inc.$13.1B
25
BTSGBrightSpring Health Services, Inc.$11.4B
91
HQYHealthEquity, Inc.$9.0B
95
TXG10X Genomics, Inc.$8.1B
94
HNGEHinge Health, Inc.$6.8B
82
WAYWaystar Holding Corp.$4.8B
34
DOCSDoximity, Inc.$4.7B
61

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Tempus AI, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest TEM news & analysis

Tempus AI: Winning With Precision Medicine

Seeking Alpha · 22 Aug 2026positive

Tempus AI acquired Personalis' cancer monitoring tests to advance its AI-driven precision medicine platform. The move builds on existing momentum from higher test average selling prices, and recent Merck and Moderna cancer vaccine developments reinforce the strategic relevance of the platform.

Why it matters — The acquisition strengthens Tempus AI's precision medicine offering and aligns with broader industry momentum in cancer diagnostics and vaccines, expanding the growth runway for its platform.

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know

The Motley Fool · 22 Aug 2026neutral

A Tempus AI director named West sold 3,000 shares valued at $161,700 on August 14, reducing their direct equity position by 8%. The sale occurred four days before the stock rallied 24%.

Why it matters — A TEM watcher would care because insider selling ahead of a sharp price gain raises questions about timing and officer-level conviction in the stock.

Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade

The Motley Fool · 22 Aug 2026neutral

Tempus AI's legal chief, Polovin, sold 30,075 shares between August 18 and August 19, generating roughly $1.5 million in proceeds. The sale was non-discretionary and made to satisfy statutory tax withholding obligations following the vesting of restricted stock units.

Why it matters — A TEM watcher would care because the transaction clarifies that the insider sale was a routine tax-related move rather than a discretionary stock disposition, providing context amid the stock's recent 75% rally.

Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know

The Motley Fool · 22 Aug 2026neutral

Tempus AI's accounting chief disposed of 6,175 shares at a weighted average price of $49.61 per share, for a total transaction value of $306,342. The sale was a "sell to cover" event to satisfy statutory tax withholding obligations following the vesting of restricted stock units.

Why it matters — TEM watchers would care because the insider transaction is a routine tax-related disposition rather than a discretionary sale, so it carries limited signal about management's view of the company.

What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing

The Motley Fool · 22 Aug 2026neutral

Tempus AI's CFO filed an insider transaction involving 48,842 shares valued at about $2.7 million. The filing describes it as a non-discretionary transaction executed to cover tax withholding obligations tied to the vesting of restricted stock units.

Why it matters — TEM watchers would note this as a routine, non-discretionary insider transaction related to RSU vesting rather than a discretionary sale of company stock.

FAQ

Frequently asked questions about TEM stock

What is the TEM stock price forecast for 2026-2027?

The 16 Wall Street analysts covering Tempus AI, Inc. have a median 12-month price target of $59, with estimates ranging from $35 to $100. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is TEM stock a buy right now?

Of the 16 analysts covering Tempus AI, Inc., 8 rate it a Buy, 7 a Hold and 1 a Sell. Ticker Nerd's systematic factor model ranks Tempus AI, Inc. 25 out of 100 across roughly 4,600 US stocks as at 21 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank TEM?

As at 21 Aug 2026, Tempus AI, Inc. ranks 25 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (80 of 100).

Will TEM stock go up?

No one can know that. What the data says: the median 12-month target from 16 analysts implies -18.8% from the last close, and Ticker Nerd's factor model ranks Tempus AI, Inc. 25 out of 100 as at 21 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the TEM stock forecast for 2030?

No analyst covering Tempus AI, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for TEM are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $100 over the next 12 months.

How has TEM stock performed over the past year?

Tempus AI, Inc. returned -5.2% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Tempus AI, Inc. do?

Tempus AI, Inc. is a healthcare technology company that applies artificial intelligence and machine learning to clinical and molecular data to support medical decision-making.

What is the latest news on TEM?

The most recent item we track (Seeking Alpha, 22 Aug 2026): "Tempus AI: Winning With Precision Medicine". Tempus AI acquired Personalis' cancer monitoring tests to advance its AI-driven precision medicine platform. The move builds on existing momentum from higher test average selling prices, and recent Merck and Moderna cancer vaccine developments reinforce the strategic relevance of the platform.

Company

About Tempus AI, Inc.

Tempus AI, Inc. is a healthcare technology company that applies artificial intelligence and machine learning to clinical and molecular data to support medical decision-making. The company operates a data and analytics platform designed to structure, integrate, and analyze diverse healthcare information, including genomic, imaging, and electronic health record data, with the goal of enabling more precise and personalized care. Tempus AI focuses on multiple therapeutic areas such as oncology, neuropsychiatry, cardiology, infectious disease, and radiology, providing tools that help clinicians interpret complex data and select appropriate diagnostics or treatment options. Its offerings include intelligent diagnostics that use AI, including generative AI, to make laboratory testing more accurate and tailored to individual patients. Headquartered in Chicago, Illinois and founded in 2015, Tempus AI today plays a notable role in the health information services segment, serving healthcare providers, life sciences companies, and research institutions that rely on data-driven insights to improve clinical workflows and patient outcomes.

CEO Mr. Eric P. Lefkofsky J.D. · 3,800 employees · United States · https://www.tempus.com